



Cancer Chemotherapy: Combination with Inhibitors

Guest Editors:

Dr. Mara Cirone

Department of Experimental
Medicine, Sapienza University of
Rome, 00161 Rome, Italy

Dr. Gabriella D’Orazi

1. Department of Neuroscience
and Imaging, University G.
D’Annunzio, 66013 Chieti, Italy
2. Department of Research, Unit
of Cellular Network and
Therapeutic Innovation, Regina
Elena National Cancer Institute,
00144 Rome, Italy

Deadline for manuscript
submissions:

closed (31 May 2023)

Message from the Guest Editors

Dear Colleagues,

Several different molecular pathways have been implicated in the development of resistance, including those regulating stress responses, such as autophagy, unfolded protein response (UPR), DNA damage response (DDR), antioxidant response, and heat shock response (HSR). Unfortunately, following the inhibition of one of the oncogenic pathways, cancer cells may hyperactivate others to keep surviving. Therefore, to combat drug resistance, combination therapies targeting several molecular pathways and their-induced protective processes seem to be more promising than a single targeted therapy especially if they result also in anti-cancer immune activation.

This Special Issue aims to collect research articles, Reviews and Communications focused on (but not limited to) *experimental* studies in the research area of chemoresistance and combination therapies with inhibitors to overcome or prevent potential drug resistance.

Dr. Mara Cirone
Dr. Gabriella D’Orazi
Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)